Pharmacotherapy · 2000
Randomized, multicenter comparison of oral granisetron and oral ondansetron for emetogenic chemotherapy.
Клиническое исследованиеСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Herrington J D, Kwan P, Young R R, Lagow E, Lagrone L, Riggs M W
Аннотация
STUDY OBJECTIVES: To compare the antiemetic effectiveness and safety of oral granisetron plus dexamethasone with those of oral ondansetron plus dexamethasone administered before emetogenic chemotherapy.
DESIGN: Randomized, prospective, multicenter, open-label study.
SETTINGS: University-teaching hospital and veterans health care system.
PATIENTS: Sixty-one chemotherapy-naïve patients scheduled to receive emetogenic antineoplastic agents.
INTERVENTION: A single-dose oral granisetron 1 mg and dexamethasone 12 mg or single-dose oral ondansetron 16 mg and dexamethasone 12 mg was administered before chemotherapy.
MEASUREMENTS AND RESULTS: Twenty-four hours after administration patients were contacted to assess nausea, emesis, and adverse events. There were no statistical differences in frequency of nausea or emesis between groups. Seventy-six percent and 82% of patients receiving ondansetron and granisetron, respectively, experienced no emesis 24 hours after chemotherapy. Complete protection from nausea occurred in 58% and 46% of patients receiving the drugs, respectively. Adverse events were similar between groups.
CONCLUSION: Oral granisetron 1 mg and ondansetron 16 mg plus dexamethasone are safe and effective in preventing nausea and vomiting related to emetogenic chemotherapy.
DESIGN: Randomized, prospective, multicenter, open-label study.
SETTINGS: University-teaching hospital and veterans health care system.
PATIENTS: Sixty-one chemotherapy-naïve patients scheduled to receive emetogenic antineoplastic agents.
INTERVENTION: A single-dose oral granisetron 1 mg and dexamethasone 12 mg or single-dose oral ondansetron 16 mg and dexamethasone 12 mg was administered before chemotherapy.
MEASUREMENTS AND RESULTS: Twenty-four hours after administration patients were contacted to assess nausea, emesis, and adverse events. There were no statistical differences in frequency of nausea or emesis between groups. Seventy-six percent and 82% of patients receiving ondansetron and granisetron, respectively, experienced no emesis 24 hours after chemotherapy. Complete protection from nausea occurred in 58% and 46% of patients receiving the drugs, respectively. Adverse events were similar between groups.
CONCLUSION: Oral granisetron 1 mg and ondansetron 16 mg plus dexamethasone are safe and effective in preventing nausea and vomiting related to emetogenic chemotherapy.